Sebastian Nijman
Associate Professor
Cancer is one of the biggest causes of death in the Western world. My group develops new approaches to study signalling networks in cancer cells and to uncover specific weaknesses that can be used for developing more effective targeted drugs and for guiding treatment decisions. We use high-throughput chemical and genetic screening approaches and haploid genetics to engineer isogenic human cancer cells and tease out chemical and genetic interactions that could be therapeutically exploited. These interactions are then studied in more detail using cell culture, mouse models, and patient samples.
Key publications
-
Targeting a cell state common to triple-negative breast cancers.
Journal article
Muellner MK. et al, (2015), Molecular systems biology, 11, 789 - 789
-
Functional genomics to uncover drug mechanism of action.
Journal article
Nijman SMB., (2015), Nature chemical biology, 11, 942 - 948
-
Parallel reverse genetic screening in mutant human cells using transcriptomics
Journal article
Nijman S. et al, (2016), Molecular Systems Biology
-
MEK inhibitors block growth of lung tumors with mutations in Ataxia Telangiectasia Mutated
Journal article
Nijman S. et al, Nature Communications
Recent publications
-
Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7
Journal article
Gerken PA. et al, (2017), Angewandte Chemie International Edition, 56, 15555 - 15559